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Abstract
The availability and adoption of modern therapeutic protocols for childhood cancer have 
continuously reduced the mortality rate of childhood malignancies in most countries 
over the past decades. Children being treated for cancer are actively growing, creating 
unique problems not only in the short-term but also in the long-term development of 
both the orofacial hard and soft tissue. Complications during and after cancer therapy 
depend on the type of malignancy, age at diagnosis, and the drugs used during the 
therapy. The adverse oral effects of irradiation have long been known, and high-dose 
chemotherapy can cause similar oral late effects, such as dental disturbances, delayed 
tooth eruption, oral mucosa changes, and craniofacial effects. There are many protocols 
to prevent acute oral toxicity and infections like mucositis, candidiasis, or hyposalivation. 
The aim of this chapter is to define the short-term and long-term effects of cancer therapy 
on the oral health.
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1. Introduction
1.1. Craniofacial development
An understanding of dental and craniofacial effects of cancer therapy is an essential knowl-
edge of distinct mechanism of postnatal craniofacial development, growth, and capacities for 
adaptation during growth.
The craniofacial complex can be organized according to four anatomic regions: desmocra-
nium, chondrocranium, splanchnocranium, and the most specialized anatomic component, 
dentition.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
There are three principal growth-related cranial base synchondroses that separate the bones 
of cranial base at birth. Fuses of intersphenoid synchondrosis finished around the time of 
birth and it does not contribute to postnatal growth. The sphenoethmoidal synchondrosis is 
most active with respect to growth of the cranial base through approximately 7 years of age 
(synchondrosis loses its cartilage phenotype). Growth of the anterior cranial base is essentially 
complete. As a result, the anterior wall of sella turcica, the greater wing of the sphenoid, and 
the cribriform plate are commonly used after age 7 as stable reference structures for analyses of 
lateral cephalograms. The third synchondrosis (sphenooccipital) is most prominent through-
out the period of active craniofacial growth and fuses only after puberty at 16–19 years.
The cranial base undergoes a dramatic shift in its growth pattern during the early postnatal 
years. Cranial base dimensions (anterior and posterior lengths) and cranial base angulations 
show greater growth changes at the age of 2 and 3 years. The changes after 2–3 years of age 
are smaller and steady. So the irradiation in this time causes the greatest cranial disturbances.
The midface at the time of birth is well developed, but slightly relative to the neurocra-
nium. Significant anterior and vertical growth of the midface through the first several years 
after birth can be observed due to interstitial cartilaginous growth of midline nasal septum. 
Nasomaxillary complex of postnatal development occurs via intramembranous ossification 
except nasal septum. Growth at the sutures of midface leads to inferior and anterior, and lat-
eral midfacial displacements means vertical, transverse, and anteroposterior changes. Growth 
continues until premaxillary/maxillary suture closes at 3–5 years of life [1]. The major inter-
maxillary growth sites are midpalatal and transpalatal sutures, associated with transverse 
and anteroposterior midface growth. Growth of midpalatal and transpalatal sutures contin-
ues until 20–25 years of age [2, 3]. The midface undergoes a complex remodeling pattern 
throughout childhood and adolescence. The length of entire maxilla and dental arches, and 
height of the midface are increased by continued development of the dentition and alveolar 
bone. Growth of cranial base displaces the maxilla in a downward and forward direction 
[4]. The age of 7 years is something of a benchmark for growth of the midface [4]. Relatively, 
anterior cranial base is stable but the growth of cartilages of the nasal capsule and nasal sep-
tum changes significantly. The cartilaginous nasal capsule becomes ossified and the nasal 
septum, which remains cartilaginous throughout life, decreases significantly in growth activ-
ity. Structures within the midfacial complex also affect its displacement and rotation. Growth 
of the eyeball is associated with both the anterior and lateral displacements of the midface; 
enucleation of the eyeball during growth results in deficiencies in the anterior and lateral 
growth of the midface [5]. Sexual dimorphism increases substantially throughout the midfa-
cial complex. Adult males are larger and wider midfaces than females. The reason is males 
have the two extra years of childhood’s growth; males enter the adolescence phase of growth 
at 12 years of age, while females enter at 10 years.
During postnatal development, mandible increases in size as a result of the combined pro-
cesses of proliferation and ossification of secondary cartilage at the condyle, as well as differ-
ential formation and remodeling of bone along the entire surface of the mandible. Because the 
posterior mandible generally undergoes greater inferior displacement than the anterior man-
dible, the mandible rotates forward. Growth of the mandible is expressed in a downward and 
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forward growth direction relative to the rest of the cranium. In this overall pattern, the growth 
of the mandible follows the growth of the midface. As the midface is translated downward 
and forward, the mandible keeps pace in the normally growing face [4, 6]. Midfacial growth 
and the associated changes in the position of the maxillary dentition are also thought to play 
an important role in mandibular growth displacements [7–9].
1.2. Dental development
The primary (milk teeth) and secondary dentitions all form in essentially the same manner, 
although at different times. The entire primary dentition is initiated between 6th and 8th week 
in utero, the successional permanent teeth between the 20th week of embryonic develop-
ment and 21 years of age for third molar [10]. Teeth development (initiation) is regulated by 
epithelial-mesenchymal interactions between oral epithelium and neural crest-derived mes-
enchyme [11]. During the proliferation stage, tooth formation proceeds through increased 
mitotic activity, leading to the development of ameloblasts and odontoblasts, which produce 
enamel prism and dentin. The internal enamel rods will differentiate into ameloblasts and 
then begin the production of enamel rods. During histodifferentiation stage, the cells lose 
the ability to multiply. Aberrations in initiation and proliferation typically result in failure of 
tooth development, while insults during histodifferentiation result lead to abnormal structure 
of enamel and dentin (amelogenesis and dentinogenesis imperfecta, and discolored enamel). 
Disturbances during morphodifferentiation can cause abnormal shape and size of teeth. The 
next stage of individual tooth development is appositional growth, while the ameloblast and 
odontoblast produce a deposition of an extracellular (organic) matrix. The process of mineral-
ization begins with formation of small nidus (ionic calcium and phosphate precipitation), and 
this nidus increases in size and leads to homogeneously mineralized layer. Environmental 
insults during due to lack of fusion of the calcospherites, which could leads to less resistant 
to dental caries.
Root formation begins when the epithelial layers penetrate into underlying mesenchyme and 
form the Hertwig’s epithelial root sheath. This sheath grows around the dental papilla until it 
encloses the apical foramen. As a result root disturbance, which is a lack of root structure, leads 
to shortened and tapered root. Root development plays a dominant role in the eruption [6].
2. Short-term effects
Radiotherapy
Radiation therapy of children with malignancies requires attention to physical and biological 
principles to maximize efficacy and reduce late effects. Biologically, effective forms of radia-
tion produce energetic charged particles in tissue, resulting in direct and indirect ionization of 
intracellular molecules with attendant biological effect [12]. The reaction of normal tissues to 
irradiation can occur during or immediately after therapy as acute effects, within 3–6 months 
after treatment as subacute effects, and later 6 months after radiotherapy as late effects [13]. 




• Oral mucositis and stomatitis
• Xerostomia
• Infections:
•   Bacterial
•  Viral (herpes simplex, varicella zoster, and cytomegalovirus)
•  Fungal (Candida albicans)
• Bleeding: anywhere in the mouth, spontaneous or induced
• Neurotoxicity: bilateral mimics toothache
Radiation therapy






•  Viral (herpes simplex, varicella zoster, cytomegalovirus)
•  Fungal (Candida albicans)
• Trismus: inability to open mouth completely osteoradionecrosis
Hematopoietic cell transplantation (HCT)
• Oral mucositis (10–14 days posttransplant)
• Gingival hyperplasia
• Xerostomia
• Viral and fungal infections
Table 1. Short-term effects of cancer therapy in CCS.
Acute radiation injury is expressed in rapidly proliferating tissues like mucous membrane. 
Acute changes follow depletion of the actively proliferating stem cells, time of onset, and 
degree depending on the size of the stem cell compartment and response of the cell renewal 
system. Acute effects do not correlate with subacute and late parenchymal complications after 
radiotherapy [14] (Table 1).
Immediate radiation reaction often occurs xerostomia, which is symptomatically expressed 
within several days of treatment encompassing the salivary glands. The radiotherapy 
damage to the salivary glands is due to an alteration in their vascular supply.
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Saliva can become sparse, thick, and ropy after just 4–5 fractions [15]. According to Epstein et 
al. whole stimulated and resting saliva productions are decreased by 36.67 and 47.9%, respec-
tively, by the end of 1 week of RT [16]. The pH after radiation falls from 7.0 to 5.0, which 
is cariogenic [17, 18]. As the pH and buffering capacity of saliva are low, the minerals of 
enamel and dentin dissolve easily [19]. Thus, the process of remineralization of the dental 
hard tissue does not occur in the oral environment of HNC patients after radiotherapy is 
prone to demineralization. Consequently, remineralization capacity of saliva is hampered 
[19]. Accompanied by the reduced oral clearance, these effects result in troublesome changes 
of the oral flora, with an increase in acidogenic and cariogenic microorganisms (Streptococcus 
mutans, Lactobacillus, and Candida species) [20].
In Spinger’s study, it is said that irradiation is thought to have a direct destructive effect on 
dental hard tissue, especially at the dentinoenamel junction (DEJ) [21].
Chemotherapy
In therapeutic doses, actively dividing normal host tissues, such as mucosal epithelial and 
bone marrow cells, are sensitive to the cytotoxic effects of anticancer drugs [22]. Unfortunately, 
the nonselective mechanism of action and resulting low therapeutic indices of these agents 
mean that high incidence of potentially severe toxicities must be tolerated to administer effec-
tive doses [23]. The dose intensity of anticancer drugs is limited primarily. Many drugs have 
unique toxicities affecting various organs or tissues such as oral complications associated 
antimetabolites, alkylating agents, plant alkaloids, and antitumor antibiotics [24]. Therapy 
affects the oral epithelial cell directly by interfering with actual cell production, maturation, 
and replacement indirectly to bone marrow depression. Myelosuppression (neutropenia and 
thrombocytopenia) increases risk of mucosal bleeding and viral, bacterial, and fungal oral 
infection. The most frequented acute complication of methotrexate in mouth is oral intesti-
nal mucositis. Mucositis occur 5–14 days after dose [25–29]. The development of mucositis is 
related to the concentration of drug (mg/m2/week) and during exposure [30] (Table 1).
Chemotherapy not only affects the rapidly dividing oral mucosa but also alters the volume of 
saliva, microbial flora, and shelter line of the mucosa. The oral mucosa of these children have 
a greater mitotic index, so, its complications in children occur more frequently than those in 
adult patients. Clinical features include swelling, bleeding, dry mouth, desquamation of gin-
giva and palate, and cracked and dry lips.
HSCT
Stem cell transplantation is the most dramatic example of rescue approach. Children with 
malignancies are treated with lethal doses of myelosuppressive drugs or combination with 
total body irradiation and then we expect infusion of stem cell, bone marrow to prevent 
permanent marrow aplasia. The oral complications of HSCT are xerostomia, mucositis, oral 
infection, and gingival hyperplasia [31] (Table 1).
2.1. Infections (oral mucositis)
The gastrointestinal system’s mucosal toxicity is a frequent immediate or short-term side 
effect of chemotherapy. It appears only when pen torch erythema illuminates the oral cavity, 
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causing extraordinarily severe pain, and thus becoming impossible for the children to eat or 
drink. In the case of combined therapy, induced mucositis can develop, which can lead to 
bleeding and infections [32].
The most frequented causes are therapy of 5-FU, azathioprine, bleomycin, cyclophospha-
mide, dactinomycin, daunorubicin, doxorubicin, nitrogén mustards, melphalan, 6-mercapto-
purine, methotrexate, mitomycins-C, novantrone, mithramycin, procarbazine, streptozotocin, 
6-thioguanine, and vinblastine [15, 33].
Mucositis or stomatitis occurs due to the damage and destruction of epithelial cells. In prin-
ciple cancer therapy can be directly impaired by the cell maturation and replacement and 
leads to bone marrow depression- myelosuppression and immunsuppression  (neutropenia, 
thrombocytopenia) increase the viral (herpes simplex, varicella zoster, cytomegalovirus), bac-
terial and fungal (Candida albicans) infections or bleeding [25, 27–29].
In the histological aspect, collagen degradation, hyperplasia, glandular degeneration, and 
dysplasia can be observed. This means that the chemical and microbiological barrier function 
of mucosal cease and cause reduced humoral factors (antibody and antimicrobial proteins) 
formation and the agents cause infections.
Management involves maintenance of meticulous oral hygiene, prevention of infection, and 
maintenance of oral function (swallowing and chewing). Systematic analgetics, ice packs to 
throat and cheeks 4–6 times daily for 15–20 minutes. Chlorhexidine mouthwashes are not 
recommended for cytotoxic-induced mucositis [34]. The newest treatment of mucositis can 
be cryotherapy [35].
2.2. Salivary glands—hyposalivation and xerostomia
The salivary glands derive their fluid with electrolytes, small organic molecules, and macro-
molecules. Secretion occurs in response to nervous stimulation. Interference with the supply 
of blood to the gland may lead to decrease in the production of saliva [31, 36, 37]. The secre-
tory cells, the blood supply, and the nerves may all be affected by ionizing radiations. Serous 
cells are more sensitive to the radiation than the mucous secreting cells. After radiotherapy, 
the produced saliva is in reduced amount and thicker. Initially, saliva becomes more viscous 
and lubrication is decreased, as the salivary gland damage progresses. The lips become dry 
and cracked, and swallowing (dysphagia) and chewing become difficult with pain [38, 39].
The hyposalivation was regarded as a short-term side effect for quite a long-term. In the case 
of patients undergoing radiotherapy, especially in the area of head and neck irradiation (rare 
in children), immediate organ toxicity has been described, which could last there for a long 
time; the patients felt improvement just after 4–12 months [40]. According to Nemeth et al. 
study, one can draw the conclusion that hyposalivation can be regarded as a long-term side 
effect after only chemotherapy. Even if this low secretion improves under or after the direct 
treatment improved a bit, it never ever reaches the pretreatment state [41].
Unstimulated and stimulated saliva flow rate after cancer therapy (radiotherapy and che-
motherapy) shows decreasing values. It seems the minor salivary glands constantly try to 
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compensate an appropriate amount of saliva. Nemeth et al. believe that the slight damage in 
the major salivary glands caused in these children by the chemotherapy was not a real reason 
for this, since it was compensated by the minor salivary gland function and that is the reason 
why unstimulated whole saliva flow rate was normal and the buffer capacity of the saliva was 
higher than in the healthy controls [41].
Lee et al. investigated patients suffering from xerostomia and concluded that the palatal sali-
vary secretion remains held. The palatal minor salivary glands play a protection function in 
the oral cavity saliva balance with their operation after chemotherapy [42, 43].
Management involves non–alcohol-based mouth rinses, saliva substitute, methyl cellulose, 
frequent intake of water, and neutral sodium fluoride application [44].
2.3. Herpes virus
Herpes simplex manifests labial and oropharyngitis which may lead to generalized sepsis. 
Clinically, the lesions appear as clear vesicle eruptions in cluster on the erythematous base, 
but herpesvirus infection can occur as nondescript and atypical appearance.
Herpes simplex and Herpes zoster infections are acute effects, but when immunosuppression 
is protracted, persistent infection can occur as indolent ulcers [45–48].
Management includes prevention and treatment with oral or intravenous acyclovir. Oral acy-
clovir needs large doses because 20–30% of drug is absorbed (750 mg/m2 per day given every 
8 h) [45–48].
2.4. Candida
The most common mucosal infection is thrush, a superficial infection due to Candida albi-
cans. Clinically, the lesions appear as whitish plaques with indurated borders.
Careful attention should be paid to oral hygiene. Clotrimazole troches, nystatin suspension, 
and oral fluconazole are used to treat the infection (50–100 mg per day) [45, 46].
2.5. Dental caries and periodontal status
Because of the hyposalivation that is an acute side effect of cytostatic agents, children often 
consume sugary and carbonated soft drinks. As a result of this, the pH of saliva is in the acidic 
range for long periods because of the qualitative and quantitative changes in the mouth. 
Because of the oral ulceration, mucositis, and xerostomia during the treatment, the consump-
tion of solid foods may be painful for the children who prefer the soft and mushy foods.
The tooth brushing frequency unfortunately reduces and the duration becomes shorter. These 
bad habits may persist later and increase late side effects. In most of the study for DMF-T 
index, the children had mixed so we do not get a valid value. In Dens’s examination, the chil-
dren were 2–17 years old; in Alberth’s study they were 4–25 years old, while in Welbury et al., 
the oral hygiene and periodontal status of survivors of malignant cancer were between 3 and 
20 years of age [49–53].
Dental and Craniofacial Effects on Childhood Cancer Survivors
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Pajari et al. and Sonis et al. measured DMF-T index, dental hygiene, and gingival index of 
children with ALL treated. They found the caries’ frequency much higher and prevalence 
of gingivitis is more frequent in the survivor children’s group than in the healthy ones’ 
[54–56].
Ayanoglou et al. found gingival overgrowth in rats gum after cyclosporin A injection [57].
Saliva flow seems to play an important role in the rate of dental caries in this population, 
since saliva has a significant protective effect against cariogenic bacteria due to its enzymatic 
and immunological activity. The increased caries risk is correlated with the decreased saliva 
flow rate and the adverse side effect of the treatment can be hyposalivation and concomitant 
changes of oral microflora.
When teeth are located in the irradiation field, hypovascularity results in a decrease in the 
circulation through pulpal tissue and increase of the collagen cross-links hydroxylysylpyr-
idinoline and lysylpyridinoline [21]. The effect of radiation on vascular flow to the dentition 
as a whole also plays a role in this multifaceted caries-promoting cycle [58]. Caries is the 
main factor contributing to the atypical and comparatively rapid progress of irradiation car-
ies, which may not be explained by hyposalivation alone [16, 59–69]. The increased stiffness is 
hypothesized due to a radiation-induced decrease in the protein content, with a much greater 
reduction in the enamel sites as compared to dentin. These changes of mechanical properties 
and chemical composition can contribute to DEJ biomechanical failure and enamel delamina-
tion [Reed]. It was observed that minimal tooth damage occurs below 30 Gy; there was a 2–3 
times increased risk of tooth breakdown between 30 and 60 Gy likely related to salivary gland 
impact; and a more increased risk of tooth damage when the tooth-level dose is above 60 Gy 
indicating radiation-induced damage to the tooth in addition to salivary gland damage. These 
findings suggest a direct effect of radiation on tooth structure with increasing radiation dose 
to the tooth [70–75]. Thus, radiogenic dental damage is the result of reduced salivary flow, as 
well as possible direct radiogenic damage [76].
Management: try to avoid cariogenic foods and drinks. Perform routine daily personal oral 
care including biofilm removal and fluoride application (gel and rinse). Dental check up is 
useful every 3 months.
3. Late effects
Radiotherapy
Late consequences of children cancer can be anticipated based on exposures, but the magni-
tude of risk and the manifestations in an individual patient are influenced by numerous fac-
tors (Table 2). There are total dose, fraction size, organ or tissue volume, and type of machine 
energy in radiotherapy. The extent of oral late effects is dependent upon the age of the chil-
dren, at the time of treatment.
The lack of specificity of radiotherapy in terms of differentiating neoplastic cells from meta-






•  Tooth agenesis
•  Microdontia
•  Enlarged pulp chamber (taurodontism)
•  Enamel hypoplasia (hypomineralization)
•  Enamel discoloration








•  Tooth agenesis
•  Microdontia
•  Enlarged pulp chamber (taurodontism)
•  Enamel hypoplasia (hypomineralization)
•  Enamel discoloration
•  Short, tapered, and blunted roots
• Craniofacial effects
Hematopoietic cell transplantation (HCT)
• Xerostomia (respond pilocarpine injection)
• Nongingival soft tissue growth (like pyogenic granuloma)
• Exophytic soft tissue lesion
• Gingival hyperplasia
• Mucosal lichenoid changes
• Mucocele
Table 2. Late-term effects of cancer therapy in CCS.
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therapy on growing cells. Indirect effects of therapy may occur in altered hypothalamic-pitu-
itary function resulting in diminished growth hormone production [7–11].
Hard tissue development of craniofacial region occurs with intramembranous and endochon-
dral bone formation and odontogenesis, and the adjoining soft tissue influences hard tissue 
development. Radiation level of 200cGy in the patient under 6 years of age may be observed 
with microscopic changes, and when a radiation is greater than 1800 cGy, it affects the cal-
varia growth and growth in the anteroposterior length. Anomalies of cranial base and orbital 
development result in a lack of midface development. Enucleation and orbital radiotherapy in 
growing child age can inhibit the growth of bony structure and detrimental to facial growth 
especially on transverse facial development. Denys et al. said children with retinoblastoma 
treated with 3000 cGy are at high risk of craniofacial deformities. Sonis et al. studied cranio-
facial abnormalities as measured by cephalometric analysis and observed significant deficient 
mandibular development in 2400 cGy RT before 5 years of age group. Studies of mandibular 
growth suggest irradiation must exceed 1800 cGy before it is detectable clinically.
Kaste and Hopkins describe a patient with maxillary hypoplasia after 10 years of therapy.
Do not forget craniofacial growth which is not proportional. While calvarial growth is 
almost completed by age 5 years, the nasomaxillary complex and mandible continue to grow 
throughout adolescence explaining the huge differences in facial appearance of the 1 and 
18 years of age. Most studies may suggest that after 12 years of age radiation-induced facial 
growth alterations are negligible [77–81].
Growth of alveolar bone is completely dependent on the presence, eruption, and root length 
of teeth. Odontoblasts are most susceptible to low-dose radiation just prior to their initia-
tion of dentin matrix formation, because presecretory odontoblasts are rapidly proliferating. 
Following radiotherapy, odontoblastic mitotic activity ceases. Defective enamel is created, 
because osteodentin interferes with the normal interaction of dentin and enamel. Enamel and 
dentin defects lead to tooth dwarfism, blunted and tapered root, incomplete calcification, 
premature apical closure, and lack of eruption [77, 78, 82–87].
Chemotherapy
The late effects of only chemotherapy on the dental- and craniofacial development are lim-
ited but some studies of the last 10 years have been shown to affect facial growth directly in 
humans Table 2.
Two chemotherapeutic agents, methotrexate and ifosfamide are well known in the protocols. 
Both of them are well-known and documented about the negative impact on the growth of 
bone system. The folic acid antagonist methotrexate can be found in most of the protocols 
against leukemia and osteosarcoma. Methotrexate over the activity of osteoblasts and osteo-
clasts decrease the activity of the increasing negative effect on the bone volume and shape. 
Stanisavljevic and Babcock repeatedly documented osteoporosis and various fractures among 
children treated against leukemia [88]. Not only after the long-term treatment with MTX, but 
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among the osteosarcoma patients treated with high-dose methotrexate of short-term therapy, 
Ecklund et al. showed similar lesions in 1997 [89].
After cyclophosphamide analogue ifosfamide treatment, Fanconi syndrome were described 
several times, which may lead to irreversible impairment of the kidney (hypocalcemia and 
hypophosphatemia) in the isotretinoin treatment of neuroblastoma, which describes diffuse 
cortical hyperostosis, ligaments calcification, and periostitis as side effects [90].
Reade and Roberts had already described the cyclophosphamide’s negative impact on the 
development of the rat’s incisor in 1978 [91]. Burn Murdoch also mentioned the negative 
effect of cyclophosphamide [92]. Mataki et al. demonstrated the inhibition of dentinogenesis 
in the case of vinblastine and colchicine-treated rats [93]. Animal studies have shown that the 
chemotherapeutic drugs induce qualitative and quantitative changes in the dental tissue, and 
inhibit the tooth eruption and odontogenesis. The chemotherapeutic agents received between 
1 and 5 years of age have negative impact on the rapidly dividing ameloblasts and odonto-
blasts, and the disorder of the ameloblast’s production, the reduction of secretory function, 
the permeability of membrane and this can lead to the changes in calcium homeostasis. It 
causes inhibition of the formation of dentin, colchicine, vinblastine, which is dose dependent, 
of course. This was proved with animal experiments by Mataki et al. Moe et al. wrote three 
articles about the impact of vinblastine on ameloblasts in 1977 [93–96]. Lyaruu et al. studied 
the effect of actinomycin-D on the tooth development of hamsters, where it was found that 
depending on the size of the dose, the preodontoblasts necrotize, and the proliferation and 
differentiation do not occur. During their human studies, Hsieh et al. confirmed the results 
of Kaste et al., and noticed that above 7500 mg/m2 of cyclophosphamide entry, there will be 
serious dental abnormalities [85, 97].
HSCT
Chronic GVHD occurs later in the transplant course, typically after day 100. Xerostomia, 
oral mucositis, and mucosal ulceration are frequent manifestations of chronic GVHD [98]. 
Dysphagia and pain on swallowing are common effects after HSCT [99–101]. Intensive che-
motherapy and high-dose total body irradiation preceding SCT and young age at transplanta-
tion (that is mean before 6 years of age) lead to the worst dental and craniofacial late effects 
Table 2.
Calcification of permanent teeth begins after birth, taking 15–17 years (excluded third molars). 
After dental crown development, the cells of Hertwig epithelial root sheath initiate dental 
root development that can be seen on orthopantomogram or CBCT starting at age 3 years to 
8 years. It is a slow and long process. The first sign of dental disturbances can be expected in 
1–2 years. The same treatment can lead to dental agenesis or microdontia in an early age of life 
or tapered and blunted root later. The disturbing effect of HSCT is dependent on chemothera-
peutic agents and irradiation. It has been revealed in animal and in vitro studies [96, 102, 103].
Decreased salivary function is a common finding in patients with GVHD who respond well 
to pilocarpine administration [39].
Dental and Craniofacial Effects on Childhood Cancer Survivors
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3.1. Impact of cancer therapy on tooth development
3.1.1. Delayed odontogenesis
Odontoblasts’ activity decreases, which results in a change in the secretion of the microtu-
bules, and thus resulting in a different tooth crowns` and roots` development.
The cronology of human dentition may vary between wide limits nevertheless among the 
cytostatic treatments’ late side effect in delayed eruption and retention can be commonly 
seen.
Several controversial literatures can be found about the standard of the development of the 
teeth. One the most common and widest range was published by Kronfeld, in 1935, who dealt 
with the development of the teeth calcification. Kronfeld’s modified chronology is used most 
widely.
During the development of enamel, because of the inducing effects of the predentin selected 
by the odontoblasts, the ameloblasts emits dentinenamel junction, which separates the enamel 
crystals and the dentin.
The ameloblasts’ apical end is stretched and the granular texture of Tomes’ processes is 
formed. This, peeled from the cell, gives the organic matrix of the enamel prism. This is fol-
lowed by the calcification process, where millions of crystals deposit in the matrix—here 
hypomineralized enamel is formed due to the effect of cytostatics on the Ca balance) [104].
3.1.2. Dental disturbances
3.1.2.1. Enamel anomalies and hypoplasia
The cytostatic agents alter the cell cycle, the regeneration of ameloblast’s reproduction, and 
the membrane’s permeability. As a result of this process, an irregular surface of the enamel 
and enamel matrix is created, which changes the opacity of the enamel, and can lead to color 
differences and hypoplasia.
In the 80% of children who sustained remission but had been treated with chemotherapy, 
structural abnormalities was found in the enamel [105–107]. Vincristine, cyclophosphamide, 
and actinomycin can disturb the odontogenesis as well. Besides this, the amelogenesis also 
becomes impaired, which may create the emergence of hypomineralized enamel [96, 108, 
109].
According a study by Alpaslan et al., among children treated with chemotherapy, the enamel 
discoloration’s frequency was 57%, while in the healthy control group received no cancer 
treatment the enamel disturbance was 13%. Hypoplasia was observed among the 47% of the 
recovered children—this value was 15% among the healthy ones [110].
Oguz’s study carried out in 2004 showed similar results. According to their study, the most 
common disorder was the enamel discoloration (67% vs. 25%) and enamel hypoplasia (56% 
vs. 44%) [111]. If the children were 5 years old or more at the time of the diagnosis of malignant 
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tumors, the enamel discoloration (71%) and the hypoplasia (58%) were significantly higher 
[111].
Minicucci et al. showed the effect of cytostatic agents causing enamel anomalies. Among the 
71 % of children treated with chemotherapy, detectable difference could be seen [112].
3.1.2.2. Dentin anomalies
Ayanoglou et al. examined the effect of cyclosporine A (CsA) in rats’ molars. The reduction 
in dentin matrix mineralization and time prolongation was observed in the process, and as a 
consequence of this, lesions similar to dentinogenesis imperfecta starts in the dentin [57, 113].
The tooth development begins to form between the 6th and the 8th week of the prenatal devel-
opment, and permanent tooth start to form in the 20th week and can last until the 21th year 
[114]. Thus, not only the in prenatal, but the postnatal diseases also can create serious malfor-
mations. The 4 years prior to the period of the tooth change are the most important and also 
the most critical period regarding the development of the permanent teeth. Chemotherapy 
given during this period has a negative impact on the rapidly dividing ameloblasts and 
odontoblasts. It can lead to malformations in the ameloblast’s productions, decrease in the 
secretory functions, and changes in membrane permeability and the calcium homeostasis. 
Colchicine and vinblastine can cause inhibit the formation of dentine, which is dose depen-
dent [93]. Moe et al. wrote three articles about the effect of vinblastine on ameloblasts in 1977 
[95, 115]. Lyaruu et al. studied the effect of actinomycin-D on the tooth development of ham-
sters. They found that, depending on the size of the dose, the preodontoblasts necrotize. The 
proliferation and differentiation does not occur. Hsieh et al. confirmed the results of Kaste 
during their human studies saying that above 7500mg/m2 cyclophosphamide entry, there 
will be serious dental abnormalities [97].
Fromm et al. studied ear, nose and throat, ophthalmological, and dental differences of chil-
dren with soft tissue sarcomas 5, 5 years after the completion of the treatment [79]. In 93% of 
the children, some dental abnormalities were found, and in 73%, there were short roots and 
agenesis. The decrease in parotid saliva production was detected in 23% of the cases.
In the study, the patients were not differentiated according to the treatment, so it is likely that 
the big difference was because of the children who underwent radiotherapy.
Estilo et al. investigated children diagnosed with head and neck region rhabdomyosarcoma 
[105]. Dental malformations were found in the case of 8 children from 10.
3.1.3. Anodontia and hypodontia
The hypodontia usually shows familiarity disorder. Acquired forms occur in children treated 
with radiation therapy or chemotherapy as the developing teeth are extremely sensitive to 
these chemical and physical disturbances.
Among children treated with chemotherapy, the frequency of hypodontia is supported by 
several international studies.
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Alpaslan et al. found hypodontia among the 50% of children treated cytotoxic due to Hodgkin 
and non-Hodgkin's lymphoma [110]. Based on studies of Oguz et al., in which 36 children 
previously treated with chemotherapy for non-Hodgkin's lymphoma were observed, they 
found agenesis in the 44% of the test group, while in the control group, they found it in only 
9 people that is 25% [111].
Kaste et al. found hypodontia in the half of 22 patients of rhabdomyosarcoma, and in 77% of 
the cases, other oral lesions were observed [84]. Kaste et al. observed 52 active children with 
neuroblastoma in the stage of tooth development. In 71% of them, dental deviations were 
detected and in 21%, hypodontia were observed [85].
Avsar et al. studied 96 malignant disease’s survivor: agenesis was found in 19.8% [116]. Holtta 
et al. observed hypodontia of 31% between the 1-year survivors of benign and malignant 
tumors [117].
3.1.4. Microdontia
Microdontia is morphological anomalies the disorders in the size and shape of the teeth. In 
order to determine the tooth size differences, we compare these differences to the permanent 
teeth during the clinical tests. Garn et al. conducted a number of studies and determined the 
size of the average values of teeth in the second half of the last century [118, 119]. There are 
several tables about these figures in Wheeler's dental anatomy book.
One of the most common disorders in the size and shape of the teeth are the microdontia and 
taurodontismus (Appendix 1). These changes cause aesthetic, functional, and occlusion prob-
lems to the patient who needs professional dental care in adult’s age.
The microdontia—similar to the hypodontia—is considered as a late side effect of radiation 
therapy, although several studies have shown that not only the X-ray radiation, but some 
cytostatics may cause microdontia, hypodontia, enamel hypoplasia, and root developmental 
differences (Appendix 1).
Minicucci et al. reported 76 children treated for cytotoxic drugs because of ALL [112]. From 
these data, it is clear that in childhood the cytostatic treatment received under the age of 6 
years can cause microdontia.
Oguz et al. found microdontia in only 1 child from 36 children treated with chemotherapy 
due to NHL [111].
Jaffe et al. tested 68 patients who had been treated against cancer earlier. Twenty-three of 
them received only chemotherapy [77]. Based on their observations, higher incidence of the 
praemolaris’ microdontia occurred in the group, which received cytostatic treatment earlier. 
This article does not mention the exact time, but most of the treatments could happen in the 
development of the premolars.
Nunn et al. [2, 120] during their examination found microdontia or indications in 27% cases 
of 52 children with hematology cancer. Less than a quarter of those children diagnosed with 
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the malignant hematological disease received radiation, and this did not affect the head and 
neck region.
Höltta et al. observed the dental differences of children treated with neuroblastoma in their 
follow-up studies. Agenesis was observed in all members of the TBI group, while relevant 
differences occurred in 40% of the chemotherapy group [121]. Microdontia was found in 80% 
cases of children participating in the study [121].
3.1.5. Root malformation
3.1.5.1. Taurodontism
Taurodens is defined as a disorder when the molar tooth crown will extend at the expense 
of the roots, so the bifurcation (or trifurcation) is close to the root tips. This means that the 
tooth will be a column, which is based on divergent short. Cytostatics received in the early 
years of life prevent or slow the formation of Hertwig epithelial root sheath, thereby forming 
taurodens [122].
Kaste et al. examined 423 children treated with ALL cytotoxic drugs. In the case of 6 % of the 
children, taurodontism was observed [86].
Jaffe et al. also observed taurodontism in children after chemotherapy. They tested 23 chil-
dren who received cytostatic treatment only, and they also showed microdontia and amelo-
genesis imperfecta differences [77].
Nunn et al. found taurodontism among the 27% of children treated with chemotherapy [120].
Lopes et al. found this lesion in 14% of the cases during the examination of 137 children with 
solid tumors and lymphoproliferative [123] (Appendix 1).
3.1.5.2. Thin, short, and tapered roots
The cytostatic agents change the ameloblast’s reproduction which reduces the secretory 
function, the membrane permeability, and change calcium homeostasis. This could lead to 
disorders of enamel formation, which can result in the development of thin, short, and frag-
ile roots. At the time of the tooth crown mineralization development, the root development 
begins. The crowns of the large incisors and the first molars can be seen on X-rays around at 
the age of three. As the tooth development is a long-term process, the lesions can be detected 
only after some years (Appendix 1).
The effects of cytostatic agents on the crown and root development have been supported with 
animal studies as well. Nasman et al. gave 13–30 mg/kg cyclophosphamide 1 ml of 0.9% NaCl 
to 18 between 3 and 10 days of age [124]. Disorders were found in the first and second molaris, 
and the third molars (wisdom) teeth of the rats in the SEM examinations. The first and second 
molar roots were shorter and thinner than the average. In the case of the third molars, there 
were not only differences in root development, but crown deficit was detected as well [125].
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Rosenberg et al.’s investigation confirms that the root brevity and slow mineralization are 
frequent among children with cytostatic treatment frequent [126].
Oguz et al. found root deformation in 23 teeth of nine children from the examination of 36 
children. Most of the anomalies were noticed in the lower central and lateral incisors, but the 
premolar and molar roots also showed lesion [111].
Alpaslan et al. observed premature apexification in the 6% of the patients, while other mal-
formation affecting the roots occurred with 44% incidence [110]. Kaste et al. described that in 
54% of 22 children treated with cytotoxic drugs due to rhabdomyosarcoma, some tooth root 
malformations were detected [86].
Marec-Berard et al. tested the dental developmental differences of children with Wilms’ 
tumor depending on the duration of chemotherapy [127]. At least one tooth developmental 
difference was found in 70% of the examined children. Before this, in 2002, they tested chil-
dren with Ewing sarcoma where in 50% of them, root malformations were found [128].
Rosenberg`s study examined 17 patients who received cytostatic agents because of ALL: in 
the case of 5 patients, the praemolaris’ shortened roots were well demonstrated by X-ray, and 
in the case of 13 children, much thinner roots were found [126].
Runge et al. drew attention to the orthodontic difficulties due to the malformations in the root 
development. The high forces applied to the fixed devices can trigger external resorption in 
the above shorter roots [129].
3.2. Craniofacial effects
3.2.1. Osteoporosis and catch up growing
It was assumed that the chemotherapeutic agents affect the craniofacial development. The 
only question is that these consequences are temporary or permanent changes. Vincristine 
and doxorubicin experiments in young rats by Karsila et al. showed that the first vincristine 
injection has a crucial role in the skull development, but 100 days after the exposure, the lag 
is caught up [130]. The female rats regenerated significantly faster and achieved the develop-
ment of the young rats not treated with chemotherapy. It was also found that all vincristine 
received rats’ cranial values differ from the healthy control animals and the animals treated 
with doxorubicin. The length and height of the mandible, the front and rear face height is 
significantly different in the case of the vincristine-treated rats.
The serum levels of Ca and P is normal or low, after the chemotherapy treatment since the 
suppurative treatments include vitamin D and calcium supplementation. During 1–2 years 
of chemotherapy, the bones’ mineral content is reduced so routine ultrasound bone mea-
surements are done. After the treatment, an increased 'importing' growth starts; the growth 
curve is higher than the normal increment, so the vitamin D and calcium supplementation is 
important. The permanent tooth’s development will be completed, however, and therefore 
shorter roots are established. After the end of the treatment, the bone age will be 1–1.5 years 
less compared to the chronological age, and the dental age will be 1–1.5 more years older.
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Halton et al. found abnormal extremely low-1, 25 dihydroxyvitamin D3 synthesis with calci-
uria of ALL children, which caused the deficiency of calcium and phosphorus that reduced 
bone mineralization. The children undergone cancer treatment, especially if the protocol con-
tained antifolate (MTX), alkylating agents (ifosfamide) or plain agents (cisplatin) [131, 132].
Fanconi syndrome (proximal tubular toxicity) can occur with calciuria and hypophospha-
temia. ALL Halton and his co-s examined children treated with ALL, and found changes in 
bone mineralization, in the process of vitamin D metabolism and several skeletal discrepan-
cies [132]. The amount of bone decrease and the risk of fractures increase. The bone hemo-
stasis degrades because of the decrease in the resorption of the intestinal calcium and the 
increased calcium usage. Nesbit et al. wrote about this in 1976 [133]. They diagnosed the 
signs of osteoporosis. Clinicians try to maintain a balance with bisphosphonates, inhibiting 
the increased osteoclast activity that leads to osteolysis. They prevent the formation of macro-
phages, from monocytes; reduce the phagocytosis and cytokine production.
The bone growth of children with cancer and leukemia treatment is affected by the high 
dose and intensive steroid. It is very important to notice the damage on time. (e.g., fractures, 
cartilage formation disorder, and deformity). Certain chemotherapy treatments can affect 
hormone production, which leads to osteoporosis, or thinning bones (trabecular structure 
is maintained, but the quality varies). Although the hormone levels return to normal after 
treatment, the bone density does not return to normal level. Suitable calcium and vitamin D 
supplementation is necessary. Both osteoporosis and periodontitis are risk factors but these 
lesions were not reported in children. However, differences were found in the skull’s develop-
ment. Kaste’s Working Group dealt with the issue of bone age, chronological age, and dental 
age. They found that the chronological age of the bone is lower and the dental age was signifi-
cantly higher in children who underwent cancer therapy [134].
Karsila-Tenovuo et al. tested 40 children; in the 1st group, there were 18 children who received 
1 cranial irradiation and chemotherapy, eight of them got hormone therapy. In the 2nd group, 
there were 11 children with extracranial solid tumor treated with alkylating agents, while 11 
children with Wilms’ tumor belonged to Group 3 who received only chemotherapy [135].
Normal growth was found in the second group. In the group 3, the cephalometria results 
remained within the normal range, except for certain details of the maxilla and the rear face 
height [135].
4. Common Toxicity Criteria
The WHO Common Toxicity Criteria (CTC) was founded in 1999; it currently has 4:03 ver-
sion in force, which was modified in 2010 under the name Common Terminology Criteria for 
Adverse Events (CTCAE). The table is included in the “Gastrointestinal System Differences” 
cheilitis and gingivitis, lip pain, mucositis, oral fistula, pain, periodontal disease, dental 
mal formations, dental pain, “Systemic side effects”, the facial pain, “Infectious Diseases” 
the gingivitis, the lips, mucous and infectious diseases, sinusitis salivary glands. In the 
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" musculoskeletal system diseases," the mouth bone necrosis and trismus, in the "The neu-
rological lesions" the dysgeusia, the mimical- and chewing muscle weakness, facial nerve 
lesions, trigeminal neuralgia, and sinus pain, and in the "Skin and subcutaneous lesions," the 
oral cavity, erythema multiforme, pruritus, and purpura were included.
5. Follow-up guidelines for survivors of childhood, adolescent, and 
young adult cancers
All children undergoing high-dose chemotherapy and/or radiotherapy or SCT should be 
referred for dental and oral hygiene assessment prior to commencement of therapy. All 
children with diagnosis of malignant disease should be encouraged to maintain good oral 
hygiene, which requires not only tooth brushing but proper oral hygiene during and after 
anticancer therapy. Our guidelines are shown in Figure 1.
It is important to know the possible side effects encountered in the treatment. The family must 
be provided with the proper advice according to the changed life situation (daily routine, 
nutrition, oral and dental hygiene). The play specialist has an important role in facilitating the 
child`s understanding of cancer therapy. They make use of various types of play and game 
depending on the child’s needs, age, culture issues, and understanding to provide informa-
tion about hospitalization and teach new information [136, 137].
During the treatment, a specialized team (dental hygienist) should monitor the daily oral 
hygiene routine for children, as many banal and painful infections can be prevented.
The oral hygiene habits should be immediately restored after the completion of therapy, in 
order not to increase the serious side effects.
In my opinion, the children undergone cancer therapy should be controlled in every 3 months 
during the first year, but from the next year, it does not have to be more frequent, rather more 
thorough and accurately documented. The most important is that parents do not have to for-
get the necessary check-ups.
The dental care of children with malignant disease does not differ from the healthy ones, 
except for the invasive interventions. It would be interesting and obvious that children cancer 
patients should belong to territorial care pedodontists, but unfortunately the current chil-
dren's dental network is not suitable in many countries for this because the children will not 
receive effective care.
It would be worth to follow and treat them in the university center, near the oncology centers. It 
will be good to create a patient card, where the dental status of the survivors could be followed.
It is important to mention here that cooperation between pediatric clinics and dental clinics 
should be encouraged to enforce the implication of oral preventive measures for children 
in chemotherapy in a way to improve their oral health. Clinicians and dentist should pro-
vide treatment to improve both the oral hygiene and the nutritional status of children cancer 
survivors.
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Figure 1. Dental management for children with diagnosis of malignant disease.






The cronology of human dentition may vary between wide limits nevertheless among the cyto-
static treatments’ late side effect in dentitio tarda and retention dentis can be commonly seen.
The most sensitive age for dental disturbances is 2–5 years of age. Microdontia (orange 
arrows), Delayed eruption of second premolar (blue arrow).
Shape and size of teeth




Microdontia is in the most of cases late effects of radiotherapy.
Thin, short, and tapered roots
Late effects of cancer therapy are anomalies of root development (blue circles).
Taurodens
Taurodens is defined as a disorder when the molar tooth crown will extend at the expense of 
the roots, so (red circles).
Disturbances
Delayed eruption of second premolars.
Taurodens of first molars.
Abbreviation
5-FU Fluorouracil, a drug used in medicine
ALL Acute lymphoblastic leukemia
Ca Calcium
CBCT Cone beam computed tomography
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